{"id":"https://openalex.org/W2332467358","doi":null,"title":"Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.","display_name":"Gefitinib as salvage therapy in pretreated patients with advanced non-small cell lung cancer. Data from a compassionate use program.","publication_year":2004,"publication_date":"2004-05-01","ids":{"openalex":"https://openalex.org/W2332467358","mag":"2332467358","pmid":"https://pubmed.ncbi.nlm.nih.gov/15274368"},"language":"en","primary_location":{"id":"pmid:15274368","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15274368","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},"volume":null,"type":"article","indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045384053","display_name":"Cesare Gridelli","orcid":"https://orcid.org/0000-0003-1069-597X","observed_orcids":["https://orcid.org/0000-0003-1069-597X"]},"institutions":[{"id":"https://openalex.org/I4210111929","display_name":"Azienda Ospedaliera S.Giuseppe Moscati","ror":"https://ror.org/021jxzw96","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210111929"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Cesare Gridelli","raw_affiliation_strings":["UO Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy. cgridelli@libero.it","UO Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UO Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy. cgridelli@libero.it","institution_ids":["https://openalex.org/I4210111929"]},{"raw_affiliation_string":"UO Oncologia Medica, Azienda Ospedaliera S.G. Moscati, Avellino, Italy","institution_ids":["https://openalex.org/I4210111929"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032078755","display_name":"Ant\u00f4nio Rossi","orcid":"https://orcid.org/0000-0003-3295-0345","observed_orcids":["https://orcid.org/0000-0003-3295-0345"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Antonio Rossi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5029922900","display_name":"Paolo Maione","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paolo Maione","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5063439353","display_name":"Ciro Guerriero","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ciro Guerriero","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001240893","display_name":"Giuseppe Airoma","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giuseppe Airoma","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083267605","display_name":"Giuseppe Colantuoni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Giuseppe Colantuoni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5111768256","display_name":"Maria Luisa Barzelloni","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Maria Luisa Barzelloni","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.656,"has_fulltext":false,"cited_by_count":6,"citation_normalized_percentile":{"value":0.85910287,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"24","issue":"3b","first_page":"1873","last_page":"7"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10202","display_name":"Lung Cancer Diagnosis and Treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12334","display_name":"Lung Cancer Research Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/gefitinib","display_name":"gefitinib","score":1.0},{"id":"https://openalex.org/keywords/advanced-non-small-cell-lung-cancer","display_name":"advanced non-small cell lung cancer","score":0.9139999747276306},{"id":"https://openalex.org/keywords/salvage-therapy","display_name":"salvage therapy","score":0.9279999732971191},{"id":"https://openalex.org/keywords/egfr-tyrosine-kinase-inhibitors","display_name":"EGFR tyrosine kinase inhibitors","score":0.8360000252723694},{"id":"https://openalex.org/keywords/expanded-access","display_name":"compassionate use","score":0.7160000205039978},{"id":"https://openalex.org/keywords/drug-tolerability","display_name":"drug tolerability","score":0.7919999957084656},{"id":"https://openalex.org/keywords/skin-toxicity","display_name":"skin toxicity","score":0.515999972820282},{"id":"https://openalex.org/keywords/diarrhea","display_name":"diarrhea","score":0.9309999942779541},{"id":"https://openalex.org/keywords/elevated-liver-enzymes","display_name":"elevated liver enzymes","score":0.7860000133514404},{"id":"https://openalex.org/keywords/nail-disorders","display_name":"nail disorders","score":0.7649999856948853},{"id":"https://openalex.org/keywords/epistaxis","display_name":"epistaxis","score":0.7390000224113464},{"id":"https://openalex.org/keywords/progression-free-survival","display_name":"progression-free survival","score":0.8029999732971191},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.9879999756813049}],"concepts":[{"id":"https://openalex.org/C2780580887","wikidata":"https://www.wikidata.org/wiki/Q417824","display_name":"Gefitinib","level":4,"score":0.9309070706367493},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8771753311157227},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.7653247117996216},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.650476336479187},{"id":"https://openalex.org/C2775832928","wikidata":"https://www.wikidata.org/wiki/Q407954","display_name":"Expanded access","level":2,"score":0.6191056966781616},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.61131352186203},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5260534286499023},{"id":"https://openalex.org/C29730261","wikidata":"https://www.wikidata.org/wiki/Q274160","display_name":"Toxicity","level":2,"score":0.502615213394165},{"id":"https://openalex.org/C2778820342","wikidata":"https://www.wikidata.org/wiki/Q906415","display_name":"Tyrosine-kinase inhibitor","level":3,"score":0.4700934588909149},{"id":"https://openalex.org/C2779438470","wikidata":"https://www.wikidata.org/wiki/Q424401","display_name":"Epidermal growth factor receptor","level":3,"score":0.45935750007629395},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.416348397731781},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3979077935218811},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.36670225858688354},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3543311655521393},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.2837218940258026}],"mesh":[{"descriptor_ui":"D000077156","descriptor_name":"Gefitinib","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000369","descriptor_name":"Aged, 80 and over","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002289","descriptor_name":"Carcinoma, Non-Small-Cell Lung","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008175","descriptor_name":"Lung Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010349","descriptor_name":"Patient Compliance","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011799","descriptor_name":"Quinazolines","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D016879","descriptor_name":"Salvage Therapy","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"pmid:15274368","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15274368","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Anticancer research","raw_type":"Journal Article"},{"id":"mag:2332467358","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/15274368","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/observational-study","display_name":"Observational Study"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2354391067","https://openalex.org/W2071995654","https://openalex.org/W2390612351","https://openalex.org/W2005779868","https://openalex.org/W2346760159","https://openalex.org/W2354924395","https://openalex.org/W2034704195","https://openalex.org/W1998373170","https://openalex.org/W2380270038","https://openalex.org/W2377944521"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1],"evaluate":[2],"the":[3,39],"tolerabiliy":[4],"and":[5,74,88,103,119,137,142,151],"activity":[6],"of":[7,41,65,128,132],"gefitinib,":[8],"an":[9,125],"epidermal":[10],"growth":[11],"factor":[12],"receptor":[13],"tyrosine":[14],"kinase":[15],"inhibitor,":[16],"in":[17,55,71,82,91,99,105,130,153],"patients":[18,47,155],"with":[19,124],"pretreated":[20,154],"advanced":[21,45,158],"non-small":[22],"cell":[23],"lung":[24],"cancer":[25],"(NSCLC).":[26],"MATERIALS":[27],"AND":[28],"METHODS:":[29],"From":[30],"July":[31],"2001":[32],"to":[33],"August":[34],"2003,":[35],"we":[36],"analysed,":[37],"retrospectively,":[38],"data":[40],"125":[42],"previously":[43],"treated":[44],"NSCLC":[46],"receiving":[48],"gefitinib":[49],"250":[50],"mg,":[51],"orally":[52],"once":[53],"daily":[54],"a":[56],"compassionate":[57],"use":[58],"program.":[59],"RESULTS:":[60],"Main":[61],"toxicity":[62],"was":[63],"(%":[64],"patients):":[66],"grade":[67],"1-2":[68],"skin":[69],"changes":[70],"7":[72],"(5.0%)":[73],"8":[75],"(6.4%)":[76],"patients,":[77],"respectively.":[78,95,145],"Grade":[79,86,96],"1":[80,87,92,100,106,111],"diarrhea":[81],"16":[83],"(12.8%)":[84],"patients.":[85],"2":[89,97],"hypertransaminasemia":[90],"(0.8%)":[93,101,107],"patient,":[94],"onychopathy":[98],"patient":[102],"epistaxis":[104],"case.":[108],"There":[109],"were":[110,140],"complete":[112],"response":[113],"(0.8%),":[114],"6":[115],"partial":[116],"responses":[117],"(4.8%)":[118],"22":[120],"(17.6%)":[121],"stable":[122],"disease":[123,129],"overall":[126,138],"control":[127],"23.2%":[131],"cases.":[133],"Median":[134],"progression-free":[135],"survival":[136,139],"8.8":[141],"21.5":[143],"weeks,":[144],"CONCLUSION:":[146],"Gefitinib":[147],"is":[148],"active,":[149],"feasible":[150],"well-tolerated":[152],"affected":[156],"by":[157],"NSCLC.":[159]},"counts_by_year":[],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}